Charles River Laboratories EBITDA 2010-2024 | CRL

Charles River Laboratories EBITDA for the quarter ending June 30, 2024 was $0.238B, a 2.01% decline year-over-year.

  • Charles River Laboratories 2023 EBITDA was 0.931B, a 2.46% decline from 2022.
  • Charles River Laboratories 2022 EBITDA was 0.955B, a 11.63% increase from 2021.
  • Charles River Laboratories 2021 EBITDA was 0.855B, a 28.12% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Charles River Laboratories EBITDA 2010-2024 | CRL

  • Charles River Laboratories 2023 EBITDA was 0.931B, a 2.46% decline from 2022.
  • Charles River Laboratories 2022 EBITDA was 0.955B, a 11.63% increase from 2021.
  • Charles River Laboratories 2021 EBITDA was 0.855B, a 28.12% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$98B
Cencora (COR)$48.9B
DiDi Global (DIDIY)$23.6B
ICON (ICLR)$17.7B
Natera (NTRA)$16.6B
Viatris (VTRS)$15.5B
Avantor (AVTR)$15.4B
Revvity (RVTY)$14.9B
BioMerieux (BMXMF)$13.1B
CochLear (CHEOY)$12.6B
Solventum (SOLV)$12.5B
Medpace Holdings (MEDP)$11.3B
Doximity (DOCS)$10.8B
HealthEquity (HQY)$8.6B
Sonic Healthcare (SKHHY)$8.5B
Bausch + Lomb (BLCO)$7B
Life Times (LTH)$5.2B
Sotera Health (SHC)$4.6B
Organon (OGN)$4.1B
Surgery Partners (SGRY)$3.9B
BrightSpring Health Services (BTSG)$3.4B
PACS (PACS)$3.3B
Alignment Healthcare (ALHC)$2.6B
Concentras Parent (CON)$2.5B
Ardent Health Partners (ARDT)$2.3B
Premier (PINC)$2.3B
GeneDx Holdings (WGS)$2.1B
Ryman Healthcare (RYHTY)$2B
GoodRx Holdings (GDRX)$1.9B
Teladoc Health (TDOC)$1.6B